|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | 64.16% | Shs Outstand | 11.63M | Perf Week | -21.58% |
Market Cap | 26.18M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 3.60M | Perf Month | - |
Income | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float / Ratio | - / - | Perf Quarter | - |
Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Interest | - | Perf Half Y | - |
Book/sh | -0.14 | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 2.15 - 6.75 | Perf YTD | -47.09% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -67.70% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 1.40% | ATR | 0.70 |
Employees | 1 | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | - | Volatility | 12.87% - |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.07 | Prev Close | 2.25 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 1.08M | Price | 2.18 |
Recom | - | SMA20 | -25.26% | SMA50 | -25.26% | SMA200 | -25.26% | Volume | 48,286 | Change | -3.11% |
![]() | ||||||||||||||||
![]() | ||||||||||||||||
|
||||||||||||||||
![]() | ||||||||||||||||
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. | ||||||||||||||||
![]() | ||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite